Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00548353 | A Study of Gastric Delay in Migraine Patients (3207-003) | PHASE1 | COMPLETED | 22 | — | — | Aug 1, 2007 | Feb 1, 2010 | Dec 19, 2014 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK3207 Orally administered to patients with water. During each period (with and without acute migraine). |
| 2 | PLACEBO_COMPARATOR | MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine). |
| Name | Type | Description |
|---|---|---|
| MK3207 | DRUG | M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets). |
| Comparator: Placebo (unspecified) | DRUG | M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets). |
Inclusion Criteria: * Non-smoking male or female between 18 to 45 years of age * Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe Exclusion Criteria: * Patient has any other medical conditions other than migraine